SARS News and Research

RSS

Evaluating the response of lung cancer patients to COVID-19 mRNA vaccination

Researchers examine the efficacy of mRNA COVID-19 vaccination in NSCLC patients.

6 Jan 2022

How effective are COVID-19 vaccines against the Omicron and Delta variants?

Researchers study the effectiveness of COVID-19 vaccines against the SARS-CoV-2 Omicron and Delta variants.

6 Jan 2022

COVID-19 vaccines effective at varying intensities of SARS-CoV-2 exposure

Researchers investigate the effectiveness of COVID-19 vaccines in individuals at high risk due to their proximity with infected individuals.

6 Jan 2022

Scientists assess effectiveness of neutralizing antibodies against seven SARS-CoV-2 variants, including Omicron

Researchers determine the neutralization potency of serum from COVID-19-recovered patients and double-vaccinated individuals against SARS-CoV-2 variants.

6 Jan 2022

Antibody binding response significantly reduced for Omicron compared to other SARS-CoV-2 variants

Researchers analyzed ACE2-binding inhibition and antibody binding for the SARS-CoV-2 Omicron variants in individuals with varying levels of immunity.

6 Jan 2022

Researchers create new monoclonal antibody treatment effective against both Delta and Omicron

In a new study, researchers conducted surface plasmon resonance experiments using commercially sourced SARS-CoV-2 protein reagents.

6 Jan 2022

Study suggests that previous COVID-19 infections do not affect pregnancy

A new study shows that it is exceedingly likely that past infection with SARS-CoV-2 has no significant effect on antibody or cytokine levels during pregnancy, labor or delivery.

6 Jan 2022

Researchers outline characteristics of Omicron variant immune escape and viral entry into host cells

A new study found that the Omicron variant contains a number of mutations that decrease neutralizing antibody activity and immune escape.

6 Jan 2022

Study identifies current mechanism of action behind reduced severity of Omicron variant COVID-19 infection

New research shows evidence that the Omicron variant is less severe compared to the Delta variant.

6 Jan 2022

Emergence of a new SARS-CoV-2 variant from Southern France

A new study has described the emergence of another new SARS-CoV-2 variant from south-eastern France with Cameroonian origin.

6 Jan 2022

Small molecule identified as a SARS-CoV-2 inhibitor

A new study published in iScience reports the results of a screening strategy to identify small molecules that target viral entry to block infection with this virus.

6 Jan 2022

Host kinase identified as an inhibition target for SARS-CoV-2

In this experiment, the chemical probe SGC-CK2-1 inhibited virus replication at nanomolar concentration, showing a highly selective effect on the kinase.

6 Jan 2022

Exploring a micro-simulation study on shielding individuals at high risk of COVID-19

A new study used an individual-based mathematical model to simulate the evolution of COVID-19 in a population, where a fraction of high-risk individuals is relocated to shielding residences having varying degrees of contact with others.

6 Jan 2022

Serological antibody response to SARS-CoV-2 infection at a population level

The scientists in this study used pooled convalescent serum to examine the serologic response in a population at risk of infection.

6 Jan 2022

Study finds all three proteins required for SARS-CoV-2 infection present in human glossopharyngeal and vagal nerves

Researchers explored the presence of coronavirus receptors in the glossopharyngeal and vagal cranial nerves.

6 Jan 2022

Melatonin found to inhibit SARS-CoV-2 entry into mice brains

New research recently unveiled the utility of melatonin and melatonin-derived medicines in reducing brain entry of severe acute respiratory syndrome coronavirus 2 and subsequently preventing long-term neurological consequences of coronavirus disease 2019.

6 Jan 2022

Comparison of neutralization of SARS-CoV-2 variants of concern Omicron and Delta

The purpose of this study was to determine the breadth of neutralizing activity generated by exposure to certain SARS-CoV-2 variants, vaccinations, or both.

6 Jan 2022

Does SARS-CoV-2 Omicron variant elicited neutralizing immunity enhance that elicited by the Delta variant?

In this paper, researchers studied whether the neutralizing immunity produced by Omicron also increases neutralizing immunity of the Delta variant.

6 Jan 2022

COVID boosters hinder SARS-CoV-2 Omicron

A new preprint research paper reports on the state of current knowledge as to the immune evasion capability of this variant, linking it to the type of vaccine used and the vaccination protocol.

6 Jan 2022

SARS-CoV-2 appears to persist in organs throughout the body for months

The coronavirus disease 2019 (COVID-19), caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), leads to asymptomatic or mild symptoms in most cases. However, in a significant minority, it causes moderate or severe disease, with lung damage and sometimes multi-organ dysfunction, the origin of which is currently a matter of intense debate.

6 Jan 2022

SARS News and Research

Evaluating the response of lung cancer patients to COVID-19 mRNA vaccination

How effective are COVID-19 vaccines against the Omicron and Delta variants?

COVID-19 vaccines effective at varying intensities of SARS-CoV-2 exposure

Scientists assess effectiveness of neutralizing antibodies against seven SARS-CoV-2 variants, including Omicron

Antibody binding response significantly reduced for Omicron compared to other SARS-CoV-2 variants

Researchers create new monoclonal antibody treatment effective against both Delta and Omicron

Study suggests that previous COVID-19 infections do not affect pregnancy

Researchers outline characteristics of Omicron variant immune escape and viral entry into host cells

Study identifies current mechanism of action behind reduced severity of Omicron variant COVID-19 infection

Emergence of a new SARS-CoV-2 variant from Southern France

Small molecule identified as a SARS-CoV-2 inhibitor

Host kinase identified as an inhibition target for SARS-CoV-2

Exploring a micro-simulation study on shielding individuals at high risk of COVID-19

Serological antibody response to SARS-CoV-2 infection at a population level

Study finds all three proteins required for SARS-CoV-2 infection present in human glossopharyngeal and vagal nerves

Melatonin found to inhibit SARS-CoV-2 entry into mice brains

Comparison of neutralization of SARS-CoV-2 variants of concern Omicron and Delta

Does SARS-CoV-2 Omicron variant elicited neutralizing immunity enhance that elicited by the Delta variant?

COVID boosters hinder SARS-CoV-2 Omicron

SARS-CoV-2 appears to persist in organs throughout the body for months

Shaping the Future of Neuroscience: A Conversation with Atlas Antibodies on the MolBoolean™ and the Impact of SfN 2024

How the Arts Reshape Brain Function: Susan Magsamen on the Future of Neuroaesthetics

Inside the Alzheimer's Association: Dr. Heather Snyder on Driving Research and Collaboration

Latest News